To investigate whether predicted HLA II epitopes of adalimumab can activate T cells, 11 adalimumab-experienced RA patients were analyzed for in vitro CD4 T cell reactivity to adalimumab peptides in PBMC co-cultures (Figures 1A, B). This evidence concerns the gene CD4 and rheumatoid arthritis.